SequelSEC

Scienture Holdings, Inc. SCNX

Pharmaceutical Preparations · CIK 0001382574 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$343.64K
Fiscal year ended 2026-06-30
Operating income
-$2.70M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Scienture Holdings, Inc. (SCNX) reported revenue of $343.64K and net income of -$2.82M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Scienture Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Scienture Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302023-12-31
Revenue$343.64K$56.32K-$168.70K$590.05K$0$10.26K$53.08K$64.86K$18.70K$128.66K
Cost of revenue$7.86K$2.48K$75.11K$15.43K$0$9.58K$50.26K$60.98K$19.40K$242.62K
Gross profit$335.78K$53.85K-$243.81K$574.62K$0$673$2.82K$3.88K-$703-$113.96K
Operating income-$2.70M-$3.51M-$29.50M-$4.36M-$5.16M-$3.57M-$4.21M-$3.50M-$1.50M-$2.25M
Net income-$2.82M-$3.40M-$28.12M-$3.61M-$6.72M-$3.06M-$7.16M-$3.18M-$1.83M-$11.67M
Research & development$1.17M$793.98K$368.70K$169.34K$843.55K$574.68K$982.71K$1.25MUnavailableUnavailable
Weighted-average diluted sharesshares 39.62Mshares 40.63MUnavailableshares 18.96Mshares 14.14Mshares 9.43MUnavailableshares 2.37Mshares 1.41MUnavailable
Pretax incomeUnavailableUnavailable-$30.12M-$3.61M-$6.72M-$3.06M-$7.34M-$3.18M-$1.62MUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.07$-0.08Unavailable$-0.19$-0.48$-0.33Unavailable$-1.34$-1.30Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$368.79K$1.07M$1.48M$2.17M$2.93M$1.36M$1.39M$168.65K$415.42K$853.26K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Scienture Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302023-12-31
Cash & equivalents$8.19MUnavailable$6.66MUnavailable$15.39KUnavailable$308.10KUnavailableUnavailable$361
Total assets$87.73M$80.66M$84.18M$104.83M$84.18M$84.18M$104.85M$94.26M$14.85M$12.53M
Current assets$9.20M$4.77M$7.92M$1.42M$856.62K$7.83M$6.31M$7.26M$12.14M$2.75M
Total liabilities$23.63M$13.84M$14.06M$22.16M$26.43M$25.20M$25.78M$9.13M$3.06M$11.99M
Current liabilities$3.03M$2.80M$2.74M$7.35M$7.69M$7.46M$7.91M$5.41M$2.90M$11.56M
Total equity incl. NCI$64.10M$66.82M$70.12M$82.67M$77.86M$81.16M$79.07M$85.13M$11.79M$542.35K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$203.07K$210.93K$213.41K$234.52KUnavailableUnavailableUnavailable$7.88K$6.44K$968
Accounts receivable$385.31K$722.54K$731.33K$590.05KUnavailable$3.73K$11.11K$10.43K$13.09K$8.49K
GoodwillUnavailableUnavailableUnavailable$21.37M$21.37M$21.37M$21.37M$7.85MUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable$2.00M$3.58M$3.09M$2.90MUnavailableUnavailableUnavailable
Accounts payable$916.77K$1.40M$1.44M$3.67M$3.14M$3.18M$2.90M$2.90M$726.27K$1.46M

Cash flow

Scienture Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302023-12-31
Operating cash flow-$3.13M-$2.92M-$5.18M-$3.21M-$2.03M-$2.96M-$2.91M-$5.39MUnavailable-$1.02M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$120.98KUnavailable-$350.00K
Financing cash flow$10.79M-$200.00K$11.48M$3.55M$0$4.70M$2.79M-$1.87MUnavailable$1.34M
Net change in cash$7.66M-$3.12M$6.31M$340.30K-$2.03M$1.74M-$119.41K-$7.14MUnavailable-$33.72K
Stock-based compensation$103.46K$102.32K$248.46K$1.66M$162.44K$437$437UnavailableUnavailable$3.76K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$2.19MUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$461.57K$454.35KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Scienture Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302023-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$2.91MUnavailableUnavailableUnavailable
Gross margin97.7%95.6%Unavailable97.4%Unavailable6.6%5.3%6.0%-3.8%-88.6%
Operating margin-785.6%-6230.8%Unavailable-739.1%Unavailable-34814.9%-7939.6%-5392.7%-7998.8%-1751.6%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-5480.9%UnavailableUnavailableUnavailable
SBC / revenue30.1%181.7%Unavailable280.9%Unavailable4.3%0.8%UnavailableUnavailableUnavailable
Current ratio3.04x1.70x2.89x0.19x0.11x1.05x0.80x1.34x4.18x0.24x
Revenue YoY growthUnavailable449.1%-417.8%809.7%-100.0%Unavailable-58.7%-83.5%-94.9%-94.3%
Net margin-821.3%UnavailableUnavailable-611.4%UnavailableUnavailable-13493.5%-4908.3%Unavailable-9066.9%
R&D / revenue339.5%1409.6%Unavailable28.7%Unavailable5602.3%1851.3%1933.3%UnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable0.02xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SCNX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

5 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.

balance equationreview2025-06-30

Difference 20116504 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2025-03-31

Difference 22180200 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-06-30

Difference 1927475 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.